NOTICE OF PUBLIC HEARING

The Ohio Bureau of Workers' Compensation will hold a public hearing on Wednesday, October 21, 2015, at 10:00 a.m., in Room 1, Level 2, 30 West Spring Street, Columbus, Ohio 43215, to consider the following:

Amendment of the following rules for the purposes as shown below:

4123-6-21.3 Outpatient medication formulary.

1. Add reimbursement for the abuse deterrent sustained release formulation Embeda® (Morphine sulfate/naltrexone). Reimbursement will not be provided for concurrent use of more than one sustained release opioid.

2. Add reimbursement for the abuse deterrent sustained release formulation Hysingla ER® (Hydrocodone Bitartrate). Reimbursement for Hysingla ER® will be limited to a total quantity of one dose per day for all strengths of the medication. Reimbursement will not be provided for concurrent use of more than one sustained release opioid

3. Remove reimbursement for the sustained release formulation Zohydro ER® (Hydrocodone Bitartrate). This was replaced by the drug Hysingla ER® which has a higher rating for abuse deterrent technology by the FDA.

4. Add reimbursement for the drug Movantik® (Naloxegol). Reimbursement requires a prior authorization with documentation of confirmed opioid induced constipation. Reimbursement is limited of no more than 30 doses per month.

5. Add the same requirements as those on Movantik® to reimbursement for the currently covered injectable drug Relistor® (Methylnaltrexone Bromide)

6. Add reimbursement for the drug Harvoni® (Ledipasvir/Sofosbuvir). Reimbursement requires prior authorization and an allowed condition of Type 1 Hepatitis C.

7. Add reimbursement for the drug Noxafil® (Posaconazole). Reimbursement requires prior authorization and documentation of a drug resistant systemic fungal infection.

8. Add reimbursement for the drug Eliquis® (Apixaban). Reimbursement requires prior authorization and documentation of an allowed condition of atrial fibrillation, venous thrombosis or post operative venous thromboprophylaxis.

9. Add reimbursement for the drug Savaysa® (Edoxaban). Reimbursement requires prior authorization and documentation of atrial fibrillation or venous thrombosis.

The full and complete text of the proposed rules is available at the Register of Ohio (http://www.registerofohio.state.oh.us) and is on file in the office of the Secretary of State (180 East Broad Street, 15th Floor, Columbus, Ohio), the Legislative Service Commission (77 South High Street, 9th Floor, Columbus, Ohio), the office of the Joint

Committee on Agency Rule Review (77 South High Street, Concourse Level, Columbus, Ohio), the Bureau of Workers' Compensation, Legal Operations (30 West Spring Street, 26th Floor, Columbus, Ohio), the Bureau of Workers' Compensation (30 West Spring Street, Columbus, Ohio, 1st Floor, Hearing Rooms), and all service offices of the Bureau.

All interested parties will be given an opportunity to be heard. Any interested party unable to attend the public hearing may submit written comments to the undersigned prior to the public hearing at enotification@bwc.state.oh.us.

THE OHIO BUREAU OF WORKERS' COMPENSATION

Tom Sico
Assistant General Counsel, BWC
30 West Spring Street, L-26
Columbus, Ohio 43215-2256
(614) 466-6600